P601: Real World Evidence on the comparative effectiveness of Ustekinumab vs anti-TNF in Crohn’s disease with Propensity Score adjustment: maintenance phase results from the prospective observational RUN-CD studyECCO'22Year: 2022
Authors: Bokemeyer, B.(1);Plachta-Danielzik, S.(2);di Giuseppe, R.(2);Deppe, H.(3);Mohl, W.(4);Teich, N.(5);Hoffstadt, M.(6);Schweitzer, A.(7);von der Ohe, M.(8);Gauss, A.(9);Atrya, R.(10);Krause, T.(11);Blumenstein, I.(12);Höchstödter, J.(2);Hartmann, P.(3);Schreiber, S.(13);
(1)Interdisciplinary Crohn Colitis Centre Minden- Germany and Clinic of General Internal Medicine I- University Hospital Schleswig-Holstein- Campus Kiel- Germany, Gastroenterology, Minden, Germany;(2)Competence Network IBD, Kiel-Germany, Kiel, Germany;(3)Gastroenterology Practice Minden, Gastroenterology, Minden, Germany;(4)Gastroenterology Practice Saarbrücken- Germany, Gastroenterology, Saarbrücken, Germany;(5)Internistische Gemeinschaftspraxis für Verdauungs- und Stoffwechselkrankheiten Leipzig, Gastroenterology, Leipzig, Germany;(6)Gastroenterology Practice Isterlohn, Gastroenterology, Iserlohn, Germany;(7)Gastroenterology Practice Münster, Gastroenterology, Münster, Germany;(8)Gastroenterology Practice Herne, Gastroenterology, Herne, Germany;(9)University Clinics of Heidelberg-Heidelberg-Germany, Department of Gastroenterology- Internal Medicine IV, Heidelberg, Germany;(10)University Hospital Erlangen- University of Erlangen-Nürnberg Erlangen- Erlangen- Germany, Department of Medicine- Medical Clinic 1, Erlangen, Germany;(11)Gastroenterology Practice Kassel, Gastroenterology, Kassel, Germany;(12)Johann Wolfgang Goethe University Clinic- 60590 Frankfurt- Germany, Department of Gastroenterology and Clinical Nutrition, Frankfurt, Germany;(13)University Hospital Schleswig-Holstein- Campus Kiel- Germany, Clinic of General Internal Medicine I, Kiel, Germany;
P602: Tofacitinib treatment prevents post-operative recurrence of Crohn’s Disease modeled by ileocecal resection in HLA-B27 transgenic rats.ECCO'22Year: 2022
Authors: Blondeaux, A.(1);Speca, S.(2);Valibouze, C.(3);Lambin, T.(1);Dubuquoy, C.(2);Titecat, M.(4);Genoscreen, L.(5);Neut, C.(6);Genin, M.(7);Zerbib, P.(3);Foligne, B.(6);Desreumaux, P.(1);
(1)Univ. Lille- Inserm- Infinite-U1286, CHU Lille- Service des maladies de l'appareil digestif, Lille, France;(2)Univ. Lille- Inserm- Infinite-U1286, CHU Lille, Lille, France;(3)Univ. Lille - Inserm - INFINITE - U1286, CHU Lille - Département de Chirurgie Digestive, Lille, France;(4)Univ. Lille- Inserm- Infinite-U1286, CHU Lille- Service de Bactériologie, Lille, France;(5)Genoscreen, Lille, Lille, France;(6)Univ. Lille- Inserm- Infinite-U1286, Faculté de Pharmacie, Lille, France;(7)Univ. Lille, Ulr 2694, Lille, France;
P603: INSPIRE: 6-month interim analysis from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn’s disease and complex perianal fistulasECCO'22Year: 2022
Authors: Zmora, O.(1);Baumgart, D.C.(2);Faubion, W.(3);Ferrante, M.(4);Gecse, K.(5);Genestin, E.(6);Geransar, P.(6);Hantsbarger, G.(7);Karki, C.(8);Tozer, P.(9);Panés, J.(10);
(1)Shamir Medical Center, Department of Surgery, Tel Aviv, Israel;(2)University of Alberta, Division of Gastroenterology, Edmonton AB, Canada;(3)Mayo Clinic, Gastroenterology and Hepatology, Rochester- MN, United States;(4)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(5)Amsterdam UMC, Gastroenterology & Hepatology, Amsterdam, Netherlands Antilles;(6)Takeda pharmaceuticals International AG, Global Medical Affairs - Rare GI, Zurich, Switzerland;(7)Takeda Pharmaceuticals USA Inc., Safety and Health Value Statistics, Cambridge- MA, United States;(8)Takeda Pharmaceuticals USA- Inc., Global Evidence and Outcomes, Cambridge- MA, United States;(9)St Mark’s Hospital and Academic Institute, Fistula Research Unit, London, United Kingdom;(10)Hospital Clinic de Barcelona, IDIBAPS- CIBERehd, Barcelona, Spain;
P604: Infection Risk in Elderly Patients with Inflammatory Bowel Disease under anti-TNF, ustekinumab or vedolizumab biologic therapies: A Prospective Multicenter observational One-Year follow-up comparative study.ECCO'22Year: 2022
Authors: Bozon, A.(1);Serrero, M.(2);Caillo, L.(3);Gilletta, C.(4);Benezech, A.(5);Nancey, S.(6);Combes, R.(7);Danan, G.(8);Akouete, S.(1);Pages, L.(1);Bourgaux, J.F.(3);Boivineau, L.(1);Meszaros, M.(1);Altwegg, R.(1);
(1)CHU Montpellier Saint Eloi Hospital, Gastroenterology, Montpellier Cedex 5, France;(2)CHU Marseille Hospital, Gastroenterology, Marseille, France;(3)CHU Nîmes Hospital, Gastroenterology, Nîmes, France;(4)CHU Toulouse Hospital, Gastroenterology, Toulouse, France;(5)CH Avignon Hospital, Gastroenterology, Avignon, France;(6)CHU Lyon Hospital, Gastroenterology, Lyon, France;(7)Clinique Beausoleil, Gastroenterology, Montpellier, France;(8)Gastrodoc, Gastroenterology, Montpellier, France;
P605: Immunogenicity and safety of standard and third dose SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases; a prospective cohort studyECCO'22Year: 2022
Authors: Jørgensen, K.K.(1); Syversen, S.W.(2); Jyssum, I.(2,3);Tveter, A.T.(2);Tran, T.T.(4);Sexton, J.(2);Provan, S.A.(2);Mjaaland , S.(5);Warren, D.J.(6);Kvien, T.K.(2,3);Grødeland , G.(3,4); Nissen-Meyer, L.S.(4);Ricanek, P.(1);Chopra , A.(4);Andersson, A.M.(4);Kro, G.B.(6);Jahnsen, J.(1,3);Munthe, L.A.(4,7);Haavardsholm, E.A.(2,3); Vaage, J.T.(3,4);Lund-Johansen, F.(3,8);Goll-, G.L.(2);
(1)Akershus University Hospital, Dept. of Gastroenterology, Oslo, Norway;(2)Diakonhjemmet Hospital, Division of Rheumatology and Research, Oslo, Norway;(3)Institute of Clinical Medicine, University of Oslo, Oslo, Norway;(4)Oslo University Hospital, Department of Immunology, Oslo, Norway;(5)Norwegian Institute of Public Health, Norwegian Institute of Public Health, Oslo, Norway;(6)Oslo University Hospital, Department of Medical Biochemistry, Oslo, Norway;(7)University of Oslo, KG Jebsen Centre for B cell Malignancies, Oslo, Norway;(8)University of Oslo, ImmunoLingo Convergence Center, Oslo, Norway;
P606: Use of TNF-α-antagonists and systemic steroids is associated with attenuated immunogenicity against SARS-CoV-2 in fully vaccinated patients with Inflammatory Bowel DiseaseECCO'22Year: 2022
Authors: Otten , A.T.(1);Bourgonje , A.R.(1);Horinga , P.P.(1);van der Meulen , H.H.(1);van Leer-Buter , C.C.(2);Dijkstra , G.(1);Visschedijk , M.C.(1);
(1)University Medical Center Groningen, Gastroenterology & Hepatology, Groningen, The Netherlands;(2)University Medical Center Groningen, Medical Microbiology, Groningen, The Netherlands;
P607: Efficacy and safety of tofacitinib in Ulcerative Colitis patients with extraintestinal manifestations in OCTAVE OpenECCO'22Year: 2022
Authors: Rubin , D.T.(1);Vavricka , S.R.(2);Armuzzi , A.(3);Dubinsky , M.C.(4);Sharara , A.I.(5);Modesto , I.(6);Fellmann , M.(7);Liguori , G.(8);Lawendy , N.(9);Cadatal , M.J.(10);Lichtenstein , G.R.(11);
(1)-, University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago- IL, United States;(2)University Hospital Zürich, Department of Gastroenterology and Hepatology, Zürich, Switzerland;(3)Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, IBD Unit, Rome, Italy;(4)-, Icahn School of Medicine at Mount Sinai, New York- NY, United States;(5)American University of Beirut Medical Center, Division of Gastroenterology, Beirut, Lebanon;(6)-, Pfizer Inc, New York- NY, United States;(7)-, Pfizer Switzerland AG, Zürich, Switzerland;(8)-, Pfizer Srl, Rome, Italy;(9)-, Pfizer Inc, Collegeville- PA, United States;(10)-, Pfizer Inc, Manila, Philippines;(11)Perelman School of Medicine at the University of Pennsylvania, Division of Gastroenterology, Philadelphia- PA, United States;
P608: Systematic review: The impact and importance of body composition in Inflammatory Bowel DiseaseECCO'22Year: 2022
Authors: Ding, N.(1,2);Tassone, D.(1);Al Bakir, I.(2);Wu, K.(1);Connell, W.(1);Thompson, A.(1);Malietzis, G.(3);Lung, P.(2);Singh, S.(4);Choi, C.H.(2);Gabe, S.(2);Jenkins, J.(3);Hart, A.(2);
(1)St Vincent's Hospital Melbourne, Gastroenterology, Fitzroy, Australia;(2)St Mark's Hospital and Academic Institute, Inflammatory Bowel Disease, Harrow, United Kingdom;(3)Imperial College London, Department of Surgery & Cancer, London, United Kingdom;(4)University of California San Diego, Gastroenterology, La Jolla, United States;
P610: Safety of COVID-19 vaccine in patients with Inflammatory Bowel Disease: preliminary data of a national study (ESCAPE-IBD)ECCO'22Year: 2022
Authors: Todeschini, A.(1);Macaluso, F.S.(2);Contaldo, A.(3);Mannino, M.(2);Orlando, A.(2);Principi, M.(1);
(1)A.O. Policlinico Bari, Section of Gastroenterology- Department of Emergency and Organ Transplantation., Bari, Italy;(2)''Villa Sofia-Cervello'' Hospital, IBD Unit- Department of Medicine, Palermo, Italy;(3)National Institute of Research @Saverio De Bellis@, Section of Gastroenterology II, Castellana Grotte, Italy;
P611: Serological biomarkers of type VI and XXII collagen formation predict and monitor infliximab treatment response in patients with Crohn’s diseaseECCO'22Year: 2022
Authors: Sorokina Alexdóttir, M.(1);Bourgonje, A.R.(2);Karsdal, M.A.(1);Bay-Jensen, A.C.(1);Pehrsson, M.(1);Loveikyte, R.(2);van Dullemen, H.M.(2);Visschedijk, M.C.(2);A. M. Festen, E.(2); Weersma, R.K.(2);Faber, K.N.(2);Dijkstra, G.(2);Mortensen, J.H.(1);
(1)Nordic Bioscience, Immunoscience, Herlev, Denmark;(2)University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands;
P612: Mirikizumab Pharmacokinetics and Exposure - Efficacy Relationships in Patients with Ulcerative ColitisECCO'22Year: 2022
Authors: Friedrich, S.(1);Chua, L.(1);Tuttle, J.L.(2);Feagan, B.G.(3);Sandborn, W.J.(4);
(1)Eli Lilly and Company, Immunology, Indianapolis, United States;(2)Eli Lilly and Company, Lilly Biotechnology Center, San Diego, United States;(3)Western University, Gastroenterology, London- ON, Canada;(4)University of California San Diego, Gastroenterology, La Jolla, United States;
P613: Comparative objective effectiveness of vedolizumab and ustekinumab in a real-life cohort of active Crohn’s disease patients failure to TNF inhibitors.ECCO'22Year: 2022
Authors: Onali, S.(1);Pugliese, D.(2);Caprioli, F.A.(3);Orlando, A.(4);Biancone, L.(5);Nardone, O.M.(6);Imperatore, N.(7);Fiorino, G.(8);Cappello, M.(9);Viola, A.(10);Principi, M.B.(11);Bezzio, C.(12);Aratari, A.(13);Carparelli, S.(14);Mazzuoli, S.(15);Manguso, F.(7);Grossi, L.(16);Bodini, G.(17);Ribaldone, D.(18);Mocci, G.(19);Minerba, L.(20);Favale, A.(21);Grova, M.(22);Scucchi, L.(23);Segato, S.(24);Fries, W.(25);Castiglione, F.(26);Armuzzi, A.(2);Fantini, M.C.(27);
(1)Università degli Studi di Cagliari, Scienze Mediche e Sanità Pubblica, Cagliari, Italy;(2)CEMAD – IBD UNIT - Unità Operativa Complessa di Medicina Interna e Gastroenterologia 2- Dipartimento di Scienze Mediche e Chirurgiche- Fondazione Policlinico Universitario @A. Gemelli@ IRCCS- Rome- Italy., Dipartimento Universitario di Medicina e Chirurgia Traslazionale- Università Cattolica del Sacro Cuore., Roma, Italy;(3)Università degli Studi di Milano- Italy. Gastroenterology and Endoscopy Unit- Fondazione IRCCS Cà Granda- Ospedale Maggiore Policlinico di Milano- Italy, Department of Pathophysiology and Transplantation-, Milano, Italy;(4)IBD UNIT @Villa Sofia Cervello@ Hospital- Palermo- Italy, ibd unit, palermo, Italy;(5)- University of Rome “ Tor Vergata”- Rome- Italy, Department of Systems Medicine, roma, Italy;(6)AOU Federico II Napoli- Italy, Department of Clinical Medicine and Surgery-, Napoli, Italy;(7)AORN A. Cardarelli of Naples- Italy, Gastroenterology and Endoscopy Unit, Napoli, Italy;(8)Humanitas University- Pieve Emanuele- Milan- Italy, Department of Biomedical Sciences, Milano, Italy;(9)University of Palermo- Sicily- Italy, IBD Clinic- Gastroenterology Section- Promise, Palermo, Italy;(10)University of Messina- Italy, IBD-Unit- Department. of Clinical and Experimental Medicine, Messina, Italy;(11)Policlinico-Università Bari- Italy, Gastroenterology Section D.E.T.O., Bari, Italy;(12)Asst Rhodense- Rho - Milan - Italy, Gastroenterology Unit, Milano, Italy;(13)Ospedale San Filippo Neri- Rome- Italy, Unità operativa semplice IBD, Roma, Italy;(14)Fondazione Casa Sollievo della Sofferenza - IRCCS - San Giovanni Rotondo- Italy, UOC di Gastroenterologia ed Endoscopia Digestiva, San Giovanni Rotondo, Italy;(15)Ospedale “Mons Raffaele Dimiccoli”- Barletta- Italy, UOC di Gastroenterologia-, Barletta, Italy;(16)G d'Annunzio University DSMOB Ospedale Spirito Santo Pescara- Italy, Gastroenterology Unit, Pescara, Italy;(17)Policlinico San Martino- Università degli studi di Genova- Genova- Italy, Gastroenterology Units-, Genova, Italy;(18)Università degli Studi di Torino- Italy, Dipartimento di Scienze Mediche, Torino, Italy;(19)G. Brotzu- Cagliari- Italy, Gastroenterologia ARNAS, Cagliari, Italy;(20)Università di Cagliari, Dip.Statistica Medica, Cagliari, Italy;(21)Università di Cagliari, UOC Gastroenterologia, Cagliari, Italy;(22)@Villa Sofia Cervello@ Hospital-- Italy, IBD unit, Palermo, Italy;(23)University of Rome “ Tor Vergata”- Italy, Department of Systems Medicine-, Rome-, Italy;(24)Ospedale di Circolo e Fondazione Macchi –, Gastroenterologia ed Endoscopia Digestiva -, Varese, Italy;(25)University of Messina- Italy, IBD-Unit- Department. of Clinical and Experimental Medicine-, Messina, Italy;(26)AOU Federico II Napoli- Italy, Gastroenterology- Department of Clinical Medicine and Surgery, Napoli, Italy;(27)Università di Cagliari, Departement of Medical Science and Public Health, Cagliari, Italy;
P614: Proactive infliximab is superior to either conventional infliximab and vedolizumab in Inflammatory Bowel DiseaseECCO'22Year: 2022
Authors: Rodrigues, I.(1);Serrazina, J.(1);Botto, I.(1);Fernandes, S.(1);Bernardo, S.(1);Gonçalves, A.R.(1);Moura Santos, P.(1);Valente, A.(1);Correia, L.(1);Tato Marinho, R.(1);
(1)Centro Hospitalar Universitário de Lisboa Norte - Hospital de Santa Maria, Gastroenterology, Lisbon, Portugal;
P615: Improving IBD monitoring by understanding preanalytical faecal calprotectin variabilityECCO'22Year: 2022
Authors: Schröder, O.(1,2);Farrag, K.(1,2);Böcher, A.(3);Helmschrodt, A.(3);Aksan, A.(2,4);Ehehalt, R.(5);Stein, J.M.(1,2,6);
(1)DGD Clinics Sachsenhausen, Department of Gastroenterology and Clinical Nutrition, Frankfurt am Main, Germany;(2)Interdisciplinary Crohn-Colitis Centre Rhein-Main, Scientific Research, Frankfurt am Main, Germany;(3)Immundiagnostik AG, Analytic Services, Bensheim, Germany;(4)Justus-Liebig University Giessen, Institute of Nutritional Science, Giessen, Germany;(5)Gastroenterological Practice, Clinical Research, Heidelberg, Germany;(6)Goethe University Frankfurt, Institute of Pharmaceutical Chemistry, Frankfurt am Main, Germany;
P616: Safety of COVID-19 vaccines in patients with IBDECCO'22Year: 2022
Authors: Dussias, N.(1);Carbone, A.(1);Melotti, L.(1);Privitera Hrustemovic, H.(1);Salice, M.(1);Scaioli, E.(1);Calabrese, C.(1);Rizzello, F.(1);Gionchetti, P.(1);
(1)University of Bologna, Dept. of surgical and medical sciences, Bologna, Italy;
P617: Switching from an intensified regimen of infliximab to a subcutaneous standard dose in adults with Inflammatory Bowel Disease: our experience in a tertiary hospital.ECCO'22Year: 2022
Authors: Chivato Martín Falquina , I.(1);Saiz Chumillas , R.M.(1);Arias Garcia , L.(1);Vicente González , B.(2);Revilla Cuesta , N.(2);Alba Hernández , L.(1);Andrés Pascual , L.(1);Sicilia Aladrén , B.(1);
(1)Hospital Universitario de Burgos, IBD unit- gastroenterology, Burgos, Spain;(2)Hospital Universitario de Burgos, Hospital Pharmacy, Burgos, Spain;
P618: Pre-operative oral enteral nutritional optimisation for Crohn’s disease: A retrospective UK tertiary IBD centre cohort studyECCO'22Year: 2022
Authors: Meade, S.(1);Patel, K.V.(2);Luber, R.P.(3);O’Hanlon, D.(4);Caracostea, A.(1);Pavlidis, P.(5);Honap, S.(1);Anandarajah, C.(1);Griffin, N.(6);Zeki, S.(1);Ray, S.(1);Mawdsley, J.(1);Samaan , M.A.(1);Anderson, S.H.(1);Darakhshan, A.(7);Adams, K.(7);Williams, A.(7);Sanderson, J.D.(1);Lomer, M.(4);Irving, P.M.(1);
(1)Guy's and St Thomas' Hospital, Gastroenterology, London, United Kingdom;(2)St George’s Hospital, Gastroenterology, London, United Kingdom;(3)The Alfred Hospital, Gastroenterology, Melbourne, Australia;(4)Guy's and St Thomas' Hospital, Dietetics, London, United Kingdom;(5)King's College London, School of Immunology and Microbial Sciences, London, United Kingdom;(6)Guy's and St Thomas' Hospital, Radiology, London, United Kingdom;(7)Guy's and St Thomas' Hospital, Colorectal Surgery, London, United Kingdom;
P619: Patterns of Anti-TNF Prescribing & Therapy Outcome in a Large Multicentre Cohort of Inflammatory Bowel Disease PatientsECCO'22Year: 2022
Authors: Doherty, J.(1);Stack, R.(2);O Morain, N.(2);Coe, C.(2);Corcoran, R.(3);Ryan, B.(4);Doherty, G.(2);Mc Namara, D.(5);Kevans, D.(6);
(1)St James Hospital, Gastroenterology, Dublin, Ireland;(2)Centre for Colorectal Disease- St Vincent’s University Hospital & School of Medicine- University College Dublin, Department of Gastroenterology, Dublin, Ireland;(3)St James Hospital- Dublin, Department of Gastroenterology, Dublin, Ireland;(4)Tallaght University Hospital- Dublin, Department of Gastroenterology-, Dublin, Ireland;(5)Tallaght University Hospital- Dublin, Department of Gastroenterology, Dublin, Ireland;(6)St James Hospital- Dublin, Department of Gastroenterology-, Dublin, Ireland;INITIative Ireland
